The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa

• Karen Schneider ,

  * E-mail: KSchneider@kirby.unsw.edu.au (KS); MBoyd@kirby.unsw.edu.au (MAB); DWilson@kirby.unsw.edu.au (DPW)

  Affiliation The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, New South Wales, Australia

  ⨯
• Chidi Nwizu,

  Affiliation Department of Medicine, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

  ⨯
• Richard Kaplan,

  Affiliation Desmond Tutu HIV Foundation, Cape Town, South Africa

  ⨯
• Jonathan Anderson,

  Affiliation The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, New South Wales, Australia

  ⨯
• David P. Wilson ,

  * E-mail: KSchneider@kirby.unsw.edu.au (KS); MBoyd@kirby.unsw.edu.au (MAB); DWilson@kirby.unsw.edu.au (DPW)

  Affiliation The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, New South Wales, Australia

  ⨯
• Sean Emery,

  Affiliation The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, New South Wales, Australia

  ⨯
• David A. Cooper,

  Affiliations The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, New South Wales, Australia, St. Vincent's Hospital Centre for Applied Medical Research (SVH AMR), Sydney, New South Wales, Australia

  ⨯
• Mark A. Boyd

  * E-mail: KSchneider@kirby.unsw.edu.au (KS); MBoyd@kirby.unsw.edu.au (MAB); DWilson@kirby.unsw.edu.au (DPW)

  Affiliations The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, New South Wales, Australia, St. Vincent's Hospital, Sydney, New South Wales, Australia

  ⨯